Details of Disease

General Information of Disease (ID: DIS26F9Q)

• Disease Name: Pancreatic ductal carcinoma
• Synonyms: pancreatic tubular adenocarcinoma; ductal adenocarcinoma of pancreas; pancreatic ductal carcinoma; malignant neoplasm of duct of Wirsung; ductal adenocarcinoma of the pancreas; pancreatic duct adenocarcinoma; pancreas ductal adenocarcinoma; pancreatic ductal adenocarcinoma; pancreatic duct cancer
• Disease Class: 2C10: Pancreatic cancer
• Definition: An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are usually over 50 years of age. Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation. Signs and symptoms include pain, loss of weight, and jaundice. It grows rapidly and is usually detected after it has metastasized to other anatomic sites. The prognosis is usually poor.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISKHX7S: Pancreatic adenocarcinoma
  DIS26F9Q: Pancreatic ductal carcinoma
• ICD Code:
  ICD-11: ICD-11: 2C10.0
  Expand ICD-11: '2C10.0
• Disease Identifiers:
  MONDO ID: MONDO_0005184
  UMLS CUI: C1335302
  MedGen ID: 277490
  SNOMED CT ID: 792907004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[1]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[2]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aldoxorubicin	DMHKCIS	Phase 3	NA	[4]
AM0010	DMGMNUE	Phase 3	NA	[1]
NIS793	DM8LBYT	Phase 2	NA	[5]
SBP-101	DMESA9F	Phase 1	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 138 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AGR2	TT9K86S	Limited	Biomarker	[6]
ARG2	TTV1AG6	Limited	Biomarker	[7]
BBC3	TT7JUKC	Limited	Biomarker	[8]
CBX7	TTBN3HC	Limited	Altered Expression	[9]
CCN1	TTPK79J	Limited	Biomarker	[10]
CD24	TTCTYNP	Limited	Altered Expression	[11]
CD276	TT6CQUM	Limited	Biomarker	[12]
CDH3	TTARMD9	Limited	Biomarker	[13]
CHKA	TT10AWB	Limited	Altered Expression	[14]
CHST15	TTFK7E1	Limited	Biomarker	[15]
CLCA1	TT3AF4R	Limited	Altered Expression	[16]
CLDN4	TTMTS9H	Limited	Biomarker	[17]
CXCR2	TT30C9G	Limited	Biomarker	[18]
DCLK1	TTOHTCY	Limited	Altered Expression	[19]
DKK1	TTE3RAC	Limited	Altered Expression	[20]
EIF5A	TTIVCNR	Limited	Genetic Variation	[21]
EIF5A2	TTH53G9	Limited	Biomarker	[22]
FAM83B	TT1Q347	Limited	Altered Expression	[23]
FGF10	TTNPEFX	Limited	Biomarker	[24]
FOLR2	TTT54CI	Limited	Biomarker	[25]
FOXO1	TTLRVIA	Limited	Altered Expression	[26]
GLI1	TTJOMH6	Limited	Altered Expression	[27]
GPR55	TTNET8J	Limited	Biomarker	[28]
GRK3	TT5A4DX	Limited	Altered Expression	[29]
HHAT	TT1VNCG	Limited	Biomarker	[30]
HRH2	TTQHJ1K	Limited	Biomarker	[31]
IMP3	TTEJA2R	Limited	Altered Expression	[32]
IRAK4	TTILUKB	Limited	Biomarker	[33]
ITGB6	TTKQSXZ	Limited	Biomarker	[34]
KLF4	TTTI53X	Limited	Biomarker	[35]
L1CAM	TTC9D3K	Limited	Altered Expression	[36]
LASP1	TTZJA87	Limited	Altered Expression	[37]
LGMN	TTPTWV5	Limited	Biomarker	[38]
MAZ	TT059DA	Limited	Altered Expression	[39]
MUC1	TTBHFYQ	Limited	Biomarker	[40]
MUC16	TTC1PS3	Limited	Altered Expression	[41]
NRP1	TTIPJCB	Limited	Altered Expression	[42]
NSD1	TTTSJ3H	Limited	Biomarker	[43]
NTSR1	TTTUMEP	Limited	Altered Expression	[44]
P4HA1	TTNH25W	Limited	Altered Expression	[45]
PAK4	TT7Y3BZ	Limited	Biomarker	[46]
PDCD1	TTNBFWK	Limited	Biomarker	[47]
PDZK1	TTDTBLM	Limited	Altered Expression	[48]
PKM	TT4LOT8	Limited	Altered Expression	[49]
PLAC1	TTM18HX	Limited	Altered Expression	[50]
PLD1	TT3T17P	Limited	Altered Expression	[51]
PPARGC1B	TTKSQ3W	Limited	Biomarker	[52]
PPM1A	TTLA7IX	Limited	Biomarker	[53]
PSCA	TT9T4AV	Limited	Altered Expression	[54]
REG4	TTVZEHU	Limited	Altered Expression	[55]
RICTOR	TT143WL	Limited	Biomarker	[56]
RNF43	TTD91BL	Limited	Genetic Variation	[57]
SCN8A	TT54ERL	Limited	Genetic Variation	[58]
SLC8A1	TTCF82X	Limited	Genetic Variation	[59]
SMAD7	TT0J32Z	Limited	Altered Expression	[60]
SPARC	TTBQFM7	Limited	Altered Expression	[61]
SREBF2	TTRQ4AP	Limited	Biomarker	[62]
SSRP1	TTETDKQ	Limited	Altered Expression	[63]
STK33	TTP34DQ	Limited	Biomarker	[64]
TAGLN2	TTP6BIJ	Limited	Biomarker	[65]
TFF1	TTNOJIZ	Limited	Altered Expression	[66]
TK1	TTP3QRF	Limited	Biomarker	[67]
TNC	TTUCPMY	Limited	Altered Expression	[68]
TPBG	TT70MLA	Limited	Biomarker	[69]
ULK1	TT4D7MJ	Limited	Biomarker	[70]
WNT7A	TT8NARC	Limited	Altered Expression	[71]
BRCA2	TTUARD6	Disputed	Genetic Variation	[72]
CPB1	TT4UJX5	Disputed	Biomarker	[73]
ITGA11	TTANXZ7	Disputed	Altered Expression	[74]
KDM3A	TTKXS4A	Disputed	Altered Expression	[19]
MCOLN1	TT9XBVO	Disputed	Biomarker	[75]
PDX1	TT8SGZK	Disputed	Altered Expression	[76]
ADAM8	TTQWYMD	moderate	Altered Expression	[77]
ADCYAP1R1	TT5OREU	moderate	Biomarker	[78]
AZGP1	TTUPYLV	moderate	Altered Expression	[79]
CFB	TTA0P7K	moderate	Biomarker	[80]
COASY	TT4YO0Z	moderate	Genetic Variation	[81]
COL6A3	TT5WCAH	moderate	Biomarker	[82]
CSK	TTX6F0Q	moderate	Genetic Variation	[83]
DEPTOR	TTLYP6D	moderate	Altered Expression	[84]
DPEP1	TTYUENF	moderate	Biomarker	[85]
FABP5	TTNT2S6	moderate	Altered Expression	[86]
HNRNPA2B1	TT8UPW6	moderate	Biomarker	[87]
IDUA	TT0IUKX	moderate	Biomarker	[88]
KLK6	TTLPF4X	moderate	Biomarker	[89]
NEK2	TT3VZ24	moderate	Altered Expression	[90]
PDPK1	TTYMGWX	moderate	Biomarker	[91]
RPL15	TTQRVC9	moderate	Altered Expression	[92]
SENP1	TTW9HY5	moderate	Altered Expression	[93]
STK4	TTCPLVN	moderate	Biomarker	[94]
AQP3	TTLDNMQ	Strong	Biomarker	[95]
ARG1	TT7ZQEV	Strong	Altered Expression	[96]
CCKBR	TTVFO0U	Strong	Biomarker	[97]
CDC20	TTBKFDV	Strong	Biomarker	[98]
CDC25B	TTR0SWN	Strong	Biomarker	[99]
CDK5	TTL4Q97	Strong	Posttranslational Modification	[100]
CEACAM6	TTIGH2W	Strong	Biomarker	[101]
DCK	TTJOCE4	Strong	Genetic Variation	[102]
DEK	TT1NMGV	Strong	Altered Expression	[103]
DLL4	TTV23LH	Strong	Altered Expression	[104]
DYRK1A	TTSBVFO	Strong	Biomarker	[105]
DYRK1B	TTYGQ8A	Strong	Biomarker	[106]
FOLH1	TT9G4N0	Strong	Biomarker	[107]
GOT1	TTU507L	Strong	Biomarker	[108]
IDO2	TTALN9W	Strong	Altered Expression	[109]
ISG15	TTVOH3T	Strong	Altered Expression	[110]
LGR5	TTTSGRH	Strong	Altered Expression	[111]
LIPE	TTLUQ8E	Strong	Biomarker	[112]
MIA	TT5HNVS	Strong	Genetic Variation	[113]
MSLN	TT4RXME	Strong	Biomarker	[114]
MUC17	TTVO0JU	Strong	Biomarker	[115]
NEDD9	TT1UREA	Strong	Altered Expression	[116]
NES	TTHZ752	Strong	Altered Expression	[117]
NTF4	TTIM2WO	Strong	Altered Expression	[118]
PMS1	TTX1ISF	Strong	Biomarker	[119]
PRSS1	TT2WR1T	Strong	Genetic Variation	[120]
RABL3	TTYGK57	Strong	Genetic Variation	[121]
RACK1	TTJ10AL	Strong	Biomarker	[122]
RRM2	TT1S4LJ	Strong	Altered Expression	[123]
SERPINB5	TT1KW50	Strong	Biomarker	[124]
SLC29A1	TTLXAKE	Strong	Biomarker	[125]
SLC6A14	TTB6H2S	Strong	Altered Expression	[73]
TFAP2A	TTDY4BS	Strong	Altered Expression	[126]
TRPM8	TTXDKTO	Strong	Biomarker	[127]
TTK	TTP7EGM	Strong	Biomarker	[128]
UCHL5	TTSX29Z	Strong	Biomarker	[129]
XPO1	TTCJUR4	Strong	Altered Expression	[130]
YAP1	TT8UN2D	Strong	Biomarker	[131]
ADAM9	TTTYQNS	Definitive	Biomarker	[132]
ASPH	TT2KHP7	Definitive	Biomarker	[133]
BUB1	TT78309	Definitive	Altered Expression	[134]
C1QBP	TTWTD7F	Definitive	Biomarker	[135]
CTSE	TTLXC4Q	Definitive	Biomarker	[136]
DKK2	TTST5KX	Definitive	Biomarker	[137]
LAPTM4B	TTEJQT0	Definitive	Biomarker	[138]
MAPK12	TTYT93M	Definitive	Biomarker	[139]
PRLR	TTBPXMA	Definitive	Biomarker	[140]
VSIR	TT51SK8	Definitive	Biomarker	[141]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC24A2	DTKRWE8	Limited	Biomarker	[142]
SLC28A3	DT4YL5R	Limited	Altered Expression	[143]
SLC41A1	DTB37ZE	Limited	Biomarker	[144]

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CES2	DETHCPD	moderate	Altered Expression	[145]
CYP4F2	DE3GT9C	moderate	Biomarker	[146]
CYP4F3	DEFCMPI	moderate	Biomarker	[146]
EGLN3	DEMQTKH	moderate	Altered Expression	[147]

This Disease Is Related to 218 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANLN	OTXJY54C	Limited	Biomarker	[148]
ANO6	OTTA5KQJ	Limited	Biomarker	[149]
AQP5	OT77GBY8	Limited	Altered Expression	[150]
ARHGAP15	OT9CKHDC	Limited	Biomarker	[151]
ARHGEF15	OTGHDJFP	Limited	Altered Expression	[152]
ARID1A	OTRWDV3P	Limited	Biomarker	[153]
BTF3	OT5ZZFJL	Limited	Altered Expression	[154]
CADM4	OT0TFMFE	Limited	Altered Expression	[155]
CCDC51	OTOJNHNA	Limited	Biomarker	[156]
CCDC68	OT4KF6TL	Limited	Biomarker	[157]
CCNG1	OT17IA9L	Limited	Altered Expression	[158]
CDH15	OTJ1TO02	Limited	Biomarker	[13]
CLIC4	OT6KTPKD	Limited	Biomarker	[159]
CNN2	OTH3CSXA	Limited	Altered Expression	[160]
COL11A2	OT3BQUBH	Limited	Genetic Variation	[161]
COL9A1	OTWBR27Y	Limited	Genetic Variation	[58]
COL9A2	OT1ZBDBV	Limited	Genetic Variation	[58]
COL9A3	OTCUJOEK	Limited	Genetic Variation	[58]
COMMD7	OTWWJ97D	Limited	Biomarker	[162]
COPS6	OTG9AAG0	Limited	Biomarker	[163]
CRKL	OTOYSD1R	Limited	Biomarker	[164]
CST7	OTQWZUVQ	Limited	Biomarker	[165]
CSTA	OT1K68KE	Limited	Altered Expression	[166]
DCLRE1C	OTW3KB1I	Limited	Biomarker	[167]
DCX	OTISR7K3	Limited	Altered Expression	[168]
DESI2	OTHUOKOC	Limited	Altered Expression	[169]
DTNBP1	OT9UQT2S	Limited	Biomarker	[170]
DUOX2	OTU14HCN	Limited	Altered Expression	[171]
EFNB2	OT0DCUOM	Limited	Biomarker	[172]
EI24	OTD4NOYS	Limited	Altered Expression	[173]
EIF4G1	OT2CF1E6	Limited	Biomarker	[174]
EIF6	OTEXMUED	Limited	Biomarker	[175]
EMB	OT67E3Q1	Limited	Altered Expression	[176]
EYA4	OTINGR3Z	Limited	Biomarker	[177]
FBP1	OTQBANEP	Limited	Altered Expression	[178]
FEZF1	OTRX4NOT	Limited	Biomarker	[179]
FLOT2	OTZ0QR5L	Limited	Biomarker	[180]
FUT8	OTJJCVG1	Limited	Altered Expression	[181]
GAB2	OTBFN705	Limited	Biomarker	[164]
GOLM1	OTOZSV6O	Limited	Altered Expression	[182]
GPC5	OT8NR7GC	Limited	Biomarker	[183]
GPRC5A	OTPOCWR7	Limited	Biomarker	[184]
HMGN5	OTUUAHVQ	Limited	Altered Expression	[185]
IFIT3	OTPGHZB9	Limited	Biomarker	[186]
IGF2BP3	OTB97VIK	Limited	Biomarker	[187]
IKBKG	OTNWJWSD	Limited	Biomarker	[188]
IMMP2L	OT9WGAFD	Limited	Biomarker	[189]
KLF10	OT4F4UGS	Limited	Biomarker	[190]
LTBP2	OTS88GSD	Limited	Altered Expression	[191]
MAP4K5	OTUFGLXE	Limited	Biomarker	[192]
MMUT	OTBBBV70	Limited	Biomarker	[193]
MTSS1	OT5DTDO2	Limited	Biomarker	[194]
MUC13	OTWKS9MF	Limited	Altered Expression	[195]
MUC4	OTLT11V1	Limited	Altered Expression	[196]
MUCL3	OTGAD3I0	Limited	Biomarker	[197]
MYBL2	OTZ3JX8Q	Limited	Biomarker	[198]
MYOF	OTRFC3IJ	Limited	Altered Expression	[199]
NECTIN1	OTTE5ZR6	Limited	Altered Expression	[200]
NEU2	OTW76T35	Limited	Biomarker	[201]
NUDT1	OTZSES3W	Limited	Altered Expression	[202]
NUPR1	OT4FU8C0	Limited	Biomarker	[203]
OCIAD1	OTJBY7PV	Limited	Biomarker	[204]
ORM1	OTZKSBRE	Limited	Altered Expression	[205]
PAFAH1B2	OTRDWN2V	Limited	Altered Expression	[206]
PCBP2	OTXCN9CG	Limited	Altered Expression	[207]
PCDH10	OT2GIT0E	Limited	Altered Expression	[208]
PDHX	OTG7O271	Limited	Genetic Variation	[209]
PEAK1	OTVVM637	Limited	Biomarker	[21]
PF4V1	OT2CXM6L	Limited	Biomarker	[210]
PHLPP1	OTIFXW8D	Limited	Biomarker	[211]
PIGR	OT6GLSUL	Limited	Altered Expression	[212]
PREX2	OTYT1J6J	Limited	Biomarker	[213]
PSMD11	OT8KO67V	Limited	Altered Expression	[214]
QRSL1	OTJDU2UG	Limited	Biomarker	[215]
RAB27A	OT9SQRWY	Limited	Altered Expression	[216]
RAB27B	OTPF9D0K	Limited	Altered Expression	[216]
REG3G	OTLIUY8Z	Limited	Biomarker	[217]
RNLS	OTVP2WJM	Limited	Biomarker	[218]
RO60	OTLGM5A8	Limited	Altered Expression	[219]
SAV1	OTSAEV92	Limited	Biomarker	[220]
SDS	OT5WTJ2M	Limited	Biomarker	[221]
SEMA3C	OTEGUY7F	Limited	Biomarker	[222]
SERP1	OT60XXUP	Limited	Biomarker	[223]
SKI	OT4KJ8F6	Limited	Altered Expression	[224]
SOX18	OTPUMHWA	Limited	Biomarker	[225]
SOX9	OTVDJFGN	Limited	Biomarker	[226]
SPARCL1	OT74DWMV	Limited	Altered Expression	[227]
SPPL3	OT2HLJF6	Limited	Biomarker	[189]
TAS2R10	OT4RWZZD	Limited	Biomarker	[228]
TEAD1	OTK6971C	Limited	Altered Expression	[229]
TFAP2C	OTUDIW05	Limited	Biomarker	[230]
TFPI2	OTZCRWOR	Limited	Altered Expression	[229]
TGFBR3	OTQOOUC4	Limited	Biomarker	[231]
THBS2	OTXET551	Limited	Biomarker	[232]
ALPG	OTCIM29R	Disputed	Biomarker	[233]
ASH2L	OT3HG324	Disputed	Biomarker	[234]
DAXX	OTX6O7PL	Disputed	Genetic Variation	[235]
EIF4A1	OTMTBX6N	Disputed	Biomarker	[236]
EIF4A2	OT08H03R	Disputed	Biomarker	[236]
FOXB2	OTJE3RRR	Disputed	Biomarker	[237]
GALNT5	OTCV61V1	Disputed	Altered Expression	[73]
GIPC1	OTXLVCPJ	Disputed	Biomarker	[238]
KRT10	OTSVRD3Q	Disputed	Biomarker	[239]
RASAL2	OTGMMX6W	Disputed	Biomarker	[240]
RPL17	OTTYMPS6	Disputed	Altered Expression	[241]
SPATA2	OTOA45GL	Disputed	Altered Expression	[241]
THAP9	OTY4TSJO	Disputed	Biomarker	[242]
TSPAN1	OTZQPIYK	Disputed	Altered Expression	[73]
ADAM15	OTZ7VLTP	moderate	Altered Expression	[243]
AKAP12	OTCVRDDX	moderate	Posttranslational Modification	[244]
AP2A1	OTEFZB21	moderate	Altered Expression	[126]
B3GALNT1	OT8GFSQL	moderate	Altered Expression	[245]
CD151	OTF3UZS7	moderate	Biomarker	[246]
CDCA5	OTZLCQ5U	moderate	Biomarker	[247]
CLIC3	OT5KUZ3A	moderate	Altered Expression	[248]
CLPTM1L	OTDJWQXI	moderate	Biomarker	[249]
DHX58	OT19BYB1	moderate	Biomarker	[250]
DLEC1	OTMKKBUW	moderate	Biomarker	[251]
DPYSL3	OTINJV20	moderate	Biomarker	[252]
DYNLL1	OTR69LHT	moderate	Biomarker	[251]
ESRP1	OTNCS4SL	moderate	Biomarker	[253]
FCN2	OTTHJBKZ	moderate	Biomarker	[247]
FOXL1	OT89XFPN	moderate	Altered Expression	[254]
FRAT1	OT1PS84E	moderate	Altered Expression	[255]
GCHFR	OTEOT8GI	moderate	Biomarker	[247]
GOLPH3	OTDLGYM3	moderate	Altered Expression	[256]
HOXC8	OTJUYU8J	moderate	Biomarker	[257]
ILF2	OTWWVM9X	moderate	Altered Expression	[258]
JADE1	OTBPJIRI	moderate	Biomarker	[259]
KLK10	OTD573EL	moderate	Altered Expression	[89]
LHX2	OTK61NP8	moderate	Biomarker	[260]
MAP1S	OT5WUD4C	moderate	Biomarker	[261]
MNAT1	OTXLOYCB	moderate	Biomarker	[247]
MPEG1	OT7DAO0F	moderate	Biomarker	[88]
MYO10	OTHB78ZQ	moderate	Altered Expression	[262]
NMU	OTW9X7BQ	moderate	Biomarker	[263]
NUMB	OTMB586Q	moderate	Biomarker	[264]
PA2G4	OT7IG7HT	moderate	Biomarker	[265]
PNKD	OT6G9UXN	moderate	Altered Expression	[266]
PODXL	OTPNQXF3	moderate	Biomarker	[267]
PSMG1	OTZ5I6UM	moderate	Biomarker	[78]
QSOX1	OT4ZPK4P	moderate	Altered Expression	[268]
RAB2A	OT6SK83U	moderate	Biomarker	[260]
RALGDS	OTG36NI7	moderate	Altered Expression	[269]
RASSF6	OT25GVWY	moderate	Altered Expression	[270]
RNF2	OTFPLOIN	moderate	Altered Expression	[271]
RPS27	OTFXKY7P	moderate	Biomarker	[88]
SRPX2	OT6A63TX	moderate	Biomarker	[272]
STIL	OT9799VN	moderate	Altered Expression	[273]
TBX4	OTW58FG4	moderate	Altered Expression	[274]
TM4SF1	OTY0ECQN	moderate	Altered Expression	[275]
TRIM29	OT2DNESG	moderate	Altered Expression	[276]
TTLL4	OTHEIBQG	moderate	Altered Expression	[277]
APOC1	OTA58CED	Strong	Genetic Variation	[278]
BAG3	OTVXYUDQ	Strong	Altered Expression	[110]
CCL18	OT7JYSK9	Strong	Biomarker	[279]
CDX2	OTCG4TSY	Strong	Altered Expression	[280]
CEMIP	OTK80FYN	Strong	Altered Expression	[281]
COX5A	OTP0961M	Strong	Altered Expression	[282]
CPEB4	OTW1SCZW	Strong	Biomarker	[283]
CPOX	OTIAY121	Strong	Altered Expression	[282]
CRABP2	OTY01V9G	Strong	Altered Expression	[284]
DUSP2	OTH54FMR	Strong	Altered Expression	[285]
FERMT2	OTZNPWWX	Strong	Altered Expression	[286]
FXYD3	OT9PPRHE	Strong	Altered Expression	[181]
GATA6	OTO2BC0F	Strong	Biomarker	[215]
GPC1	OTQKRSSV	Strong	Biomarker	[287]
HCLS1	OTX7WGYN	Strong	Altered Expression	[118]
HHLA2	OTYBTVQS	Strong	Biomarker	[288]
HOXB9	OTMVHQOU	Strong	Biomarker	[289]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[290]
IGSF9	OTNTKWS2	Strong	Altered Expression	[291]
IQGAP1	OTZRWTGA	Strong	Biomarker	[292]
KHSRP	OTDHZARB	Strong	Altered Expression	[118]
KLF9	OTBFEJRQ	Strong	Biomarker	[293]
LGALS4	OTKQCG0H	Strong	Altered Expression	[294]
LRG1	OTLD0KWA	Strong	Altered Expression	[295]
LUM	OTSRC874	Strong	Altered Expression	[296]
MTA2	OTCCYIQJ	Strong	Biomarker	[297]
MUC20	OTYYE1GK	Strong	Biomarker	[298]
MUC3A	OTI4XUDY	Strong	Biomarker	[115]
NRDC	OTWBBCXO	Strong	Biomarker	[299]
NSD3	OT3677ZG	Strong	Biomarker	[300]
NTS	OTPGDNQS	Strong	Altered Expression	[301]
PALB2	OT6DNDBG	Strong	Biomarker	[302]
PKHD1	OTAH8SMF	Strong	Genetic Variation	[303]
PLEC	OTU4XDEG	Strong	Altered Expression	[304]
PPP4C	OT4B0TNV	Strong	Biomarker	[305]
PTF1A	OT7SWA57	Strong	Altered Expression	[306]
RHOC	OTOLE1FT	Strong	Genetic Variation	[307]
SEL1L	OTC0FB7T	Strong	Altered Expression	[308]
SIGLEC7	OTNDLURR	Strong	Altered Expression	[118]
TFIP11	OT7NVSWU	Strong	Altered Expression	[291]
TGIF1	OTN9VHAG	Strong	Biomarker	[309]
AMFR	OTQRX7LC	Definitive	Biomarker	[310]
ARHGEF10	OTHJ1Y4I	Definitive	Biomarker	[311]
ARHGEF28	OT3F32IU	Definitive	Biomarker	[311]
ATP6AP2	OT0IABVV	Definitive	Biomarker	[312]
EHF	OTY6TPWD	Definitive	Biomarker	[313]
EPS8	OTZ6ES6V	Definitive	Biomarker	[314]
FASTKD2	OTD635WX	Definitive	Altered Expression	[315]
GGPS1	OTVEHG28	Definitive	Biomarker	[316]
INSM1	OTG8RV8E	Definitive	Altered Expression	[317]
KAT2A	OTN0W2SW	Definitive	Altered Expression	[318]
LAMTOR5	OTER0U8L	Definitive	Biomarker	[319]
LIMS1	OT729S0T	Definitive	Altered Expression	[320]
LRPAP1	OT6DVD2Q	Definitive	Biomarker	[321]
MAP2K4	OTZPZX11	Definitive	Genetic Variation	[322]
MDH1	OTJEO4E8	Definitive	Biomarker	[323]
MPP7	OT3G3HTZ	Definitive	Biomarker	[323]
NBR1	OTVRL7J9	Definitive	Biomarker	[310]
NT5C1A	OTS7UF36	Definitive	Altered Expression	[324]
PLEKHM1	OT1SLPGD	Definitive	Altered Expression	[310]
PLIN2	OTRXJ9UN	Definitive	Altered Expression	[325]
POLE	OTFM3MMU	Definitive	Altered Expression	[326]
RACGAP1	OTQE8IEH	Definitive	Biomarker	[327]
TMIGD2	OTWWAHTV	Definitive	Biomarker	[141]
TMPO	OTL68EL4	Definitive	Altered Expression	[328]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Gemcitabine FDA Label
• [3] Paclitaxel FDA Label
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT04390763) Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). U.S. National Institutes of Health.
• [6] Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.Lab Invest. 2015 Feb;95(2):193-206. doi: 10.1038/labinvest.2014.138. Epub 2014 Nov 24.
• [7] Critical role for arginase 2 in obesity-associated pancreatic cancer.Nat Commun. 2017 Aug 14;8(1):242. doi: 10.1038/s41467-017-00331-y.
• [8] Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-B signaling pathway in human pancreatic ductal adenocarcinoma.Int J Mol Sci. 2012;13(1):1186-1208. doi: 10.3390/ijms13011186. Epub 2012 Jan 20.
• [9] CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.Oncotarget. 2017 Jan 31;8(5):8010-8021. doi: 10.18632/oncotarget.14037.
• [10] CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.Mol Cancer Ther. 2019 Apr;18(4):788-800. doi: 10.1158/1535-7163.MCT-18-0899. Epub 2019 Feb 20.
• [11] Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation.J Hepatobiliary Pancreat Sci. 2017 Mar;24(3):176-184. doi: 10.1002/jhbp.429. Epub 2017 Feb 19.
• [12] Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.
• [13] Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma.Br J Cancer. 2018 Feb 20;118(4):546-557. doi: 10.1038/bjc.2017.411. Epub 2017 Nov 21.
• [14] Choline Kinase Alpha (CHK) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.Mol Cancer Ther. 2016 Feb;15(2):323-33. doi: 10.1158/1535-7163.MCT-15-0214. Epub 2016 Jan 14.
• [15] Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma.Oncol Lett. 2017 Jun;13(6):4799-4805. doi: 10.3892/ol.2017.6071. Epub 2017 Apr 21.
• [16] Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma.BMC Cancer. 2018 Nov 12;18(1):1096. doi: 10.1186/s12885-018-5013-2.
• [17] Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.Mol Imaging Biol. 2018 Apr;20(2):292-299. doi: 10.1007/s11307-017-1112-8.
• [18] Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.Oncogenesis. 2019 Jan 18;8(2):8. doi: 10.1038/s41389-018-0117-8.
• [19] The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.Gastroenterology. 2019 Dec;157(6):1646-1659.e11. doi: 10.1053/j.gastro.2019.08.018. Epub 2019 Aug 20.
• [20] Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.Clin Chim Acta. 2019 Jan;488:226-234. doi: 10.1016/j.cca.2018.11.023. Epub 2018 Nov 16.
• [21] eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cancer Res. 2017 Apr 15;77(8):1997-2007. doi: 10.1158/0008-5472.CAN-16-2594. Epub 2017 Apr 5.
• [22] N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.Exp Ther Med. 2017 Sep;14(3):2101-2107. doi: 10.3892/etm.2017.4740. Epub 2017 Jul 9.
• [23] High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation.J Cancer. 2017 Sep 12;8(16):3154-3165. doi: 10.7150/jca.20086. eCollection 2017.
• [24] Emerging Roles of Fibroblast Growth Factor 10 in Cancer.Front Genet. 2018 Oct 24;9:499. doi: 10.3389/fgene.2018.00499. eCollection 2018.
• [25] Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jun 6;8(23):37646-37656. doi: 10.18632/oncotarget.16841.
• [26] MiR-27a-regulated FOXO1 promotes pancreatic ductal adenocarcinoma cell progression by enhancing Wnt/-catenin signaling activity.Am J Transl Res. 2019 May 15;11(5):3069-3080. eCollection 2019.
• [27] Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.Cancer Res. 2016 Dec 1;76(23):7049-7058. doi: 10.1158/0008-5472.CAN-16-0715. Epub 2016 Oct 6.
• [28] GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.
• [29] High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2018 Feb;214(2):228-232. doi: 10.1016/j.prp.2017.11.013. Epub 2017 Nov 20.
• [30] Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma. Oncogene. 2015 Jan 8;34(2):263-8.
• [31] Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use.Dig Dis Sci. 2018 Nov;63(11):2840-2852. doi: 10.1007/s10620-018-5233-y. Epub 2018 Aug 29.
• [32] The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion.BMC Cancer. 2015 Apr 11;15:266. doi: 10.1186/s12885-015-1251-8.
• [33] Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4.
• [34] Integrin 6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2016 Apr;37(4):5117-31. doi: 10.1007/s13277-015-4353-7. Epub 2015 Nov 7.
• [35] Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.Int J Oncol. 2017 Oct;51(4):1239-1248. doi: 10.3892/ijo.2017.4099. Epub 2017 Aug 22.
• [36] L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression.Oncogene. 2019 Jan;38(4):596-608. doi: 10.1038/s41388-018-0458-y. Epub 2018 Aug 31.
• [37] LASP1 is a HIF1 target gene critical for metastasis of pancreatic cancer.Cancer Res. 2015 Jan 1;75(1):111-9. doi: 10.1158/0008-5472.CAN-14-2040. Epub 2014 Nov 10.
• [38] Asparaginyl endopeptidase enhances pancreatic ductal adenocarcinoma cell invasion in an exosome-dependent manner and correlates with poor prognosis.Int J Oncol. 2018 May;52(5):1651-1660. doi: 10.3892/ijo.2018.4318. Epub 2018 Mar 15.
• [39] The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.J Biol Chem. 2018 Mar 23;293(12):4334-4349. doi: 10.1074/jbc.RA117.000333. Epub 2018 Feb 6.
• [40] Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1.Lab Invest. 2017 Sep;97(9):1103-1113. doi: 10.1038/labinvest.2017.53. Epub 2017 Jun 5.
• [41] Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes ofpancreatic ductal adenocarcinoma.Surgery. 2017 Feb;161(2):373-384. doi: 10.1016/j.surg.2016.08.005. Epub 2016 Nov 9.
• [42] VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival.J Pathol. 2018 Nov;246(3):311-322. doi: 10.1002/path.5141. Epub 2018 Sep 4.
• [43] Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.Pathology. 2019 Jun;51(4):392-398. doi: 10.1016/j.pathol.2019.02.005. Epub 2019 May 3.
• [44] Preclinical Evaluation of (68)Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis.Mol Pharm. 2019 Jun 3;16(6):2776-2784. doi: 10.1021/acs.molpharmaceut.9b00283. Epub 2019 May 3.
• [45] P4HA1/HIF1 feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.Biochem Biophys Res Commun. 2019 Aug 27;516(3):606-612. doi: 10.1016/j.bbrc.2019.06.096. Epub 2019 Jun 22.
• [46] Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.
• [47] A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0.
• [48] PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.Oncotarget. 2017 Aug 24;8(42):72893-72909. doi: 10.18632/oncotarget.20552. eCollection 2017 Sep 22.
• [49] Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer.Oncol Lett. 2018 Feb;15(2):2211-2217. doi: 10.3892/ol.2017.7598. Epub 2017 Dec 13.
• [50] Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.Tumour Biol. 2017 Jun;39(6):1010428317699131. doi: 10.1177/1010428317699131.
• [51] Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients.Oncotarget. 2016 Nov 29;7(48):78557-78565. doi: 10.18632/oncotarget.12447.
• [52] The FOXO3/PGC-1 signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma.J Biol Chem. 2017 Jun 30;292(26):10813-10823. doi: 10.1074/jbc.M116.772111. Epub 2017 May 15.
• [53] Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.Hum Pathol. 2016 Sep;55:151-8. doi: 10.1016/j.humpath.2016.05.002. Epub 2016 May 16.
• [54] Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.J Nucl Med. 2018 Sep;59(9):1398-1405. doi: 10.2967/jnumed.117.207332. Epub 2018 Mar 30.
• [55] Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2018 Mar;40(3):1010428318761494. doi: 10.1177/1010428318761494.
• [56] Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.Oncotarget. 2017 Apr 11;8(15):24491-24505. doi: 10.18632/oncotarget.15524.
• [57] Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.Nat Med. 2017 Jan;23(1):60-68. doi: 10.1038/nm.4219. Epub 2016 Nov 21.
• [58] Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification.Anal Chem. 2019 Jun 18;91(12):7516-7523. doi: 10.1021/acs.analchem.8b01605. Epub 2019 May 24.
• [59] Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.Theranostics. 2018 May 23;8(12):3366-3379. doi: 10.7150/thno.23978. eCollection 2018.
• [60] miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF- signalling pathway.Br J Cancer. 2015 Apr 14;112(8):1367-75. doi: 10.1038/bjc.2015.102. Epub 2015 Mar 17.
• [61] The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection.J Cancer. 2019 Jan 1;10(3):627-633. doi: 10.7150/jca.28660. eCollection 2019.
• [62] Cilia loss sensitizes cells to transformation by activating the mevalonate pathway.J Exp Med. 2018 Jan 2;215(1):177-195. doi: 10.1084/jem.20170399. Epub 2017 Dec 13.
• [63] SOX9 inhibits -TrCP-mediated protein degradation to promote nuclear GLI1 expression and cancer stem cell properties.J Cell Sci. 2015 Mar 15;128(6):1123-38. doi: 10.1242/jcs.162164. Epub 2015 Jan 27.
• [64] STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1.Cancer Res. 2017 Dec 15;77(24):6851-6862. doi: 10.1158/0008-5472.CAN-17-0067. Epub 2017 Oct 16.
• [65] Role of transgelin-2 in diabetes-associated pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jul 25;8(30):49592-49604. doi: 10.18632/oncotarget.17519.
• [66] Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer.Pancreatology. 2017 Sep-Oct;17(5):782-787. doi: 10.1016/j.pan.2017.07.188. Epub 2017 Jul 26.
• [67] Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.Cell Prolif. 2018 Jun;51(3):e12428. doi: 10.1111/cpr.12428. Epub 2017 Dec 20.
• [68] Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma.Pancreas. 2019 Jan;48(1):43-48. doi: 10.1097/MPA.0000000000001195.
• [69] Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling.Mol Med Rep. 2015 Jul;12(1):503-9. doi: 10.3892/mmr.2015.3412. Epub 2015 Mar 4.
• [70] LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis.Mol Cancer. 2018 Jul 12;17(1):98. doi: 10.1186/s12943-018-0845-6.
• [71] High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma.Sci Rep. 2018 Oct 25;8(1):15792. doi: 10.1038/s41598-018-34094-3.
• [72] Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.Int J Cancer. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7.
• [73] Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.Math Biosci Eng. 2019 Nov 6;17(1):910-927. doi: 10.3934/mbe.2020048.
• [74] 111 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration.Cancers (Basel). 2019 Jun 1;11(6):765. doi: 10.3390/cancers11060765.
• [75] MCOLN1 Promotes Proliferation and Predicts Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma.Dis Markers. 2019 Aug 5;2019:9436047. doi: 10.1155/2019/9436047. eCollection 2019.
• [76] PDX1, a key factor in pancreatic embryogenesis, can exhibit antimetastatic activity in pancreatic ductal adenocarcinoma.Cancer Manag Res. 2019 Jul 26;11:7077-7087. doi: 10.2147/CMAR.S209940. eCollection 2019.
• [77] ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.J Cell Mol Med. 2007 Sep-Oct;11(5):1162-74. doi: 10.1111/j.1582-4934.2007.00082.x.
• [78] Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.J Med Chem. 2008 Dec 11;51(23):7593-601. doi: 10.1021/jm8005965.
• [79] AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF--mediated ERK signaling.Oncogene. 2010 Sep 16;29(37):5146-58. doi: 10.1038/onc.2010.258. Epub 2010 Jun 28.
• [80] Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.J Proteome Res. 2014 Nov 7;13(11):4878-88. doi: 10.1021/pr5002719. Epub 2014 Aug 8.
• [81] Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu.Curr Opin Gastroenterol. 2012 Sep;28(5):516-22. doi: 10.1097/MOG.0b013e3283567f69.
• [82] Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.J Gastrointest Surg. 2014 Jan;18(1):7-15. doi: 10.1007/s11605-013-2326-y. Epub 2013 Sep 4.
• [83] Oncogenic Ras/Src cooperativity in pancreatic neoplasia.Oncogene. 2011 May 5;30(18):2123-34. doi: 10.1038/onc.2010.589. Epub 2011 Jan 17.
• [84] DEPTOR has growth suppression activity against pancreatic cancer cells.Oncotarget. 2014 Dec 30;5(24):12811-9. doi: 10.18632/oncotarget.2659.
• [85] DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.
• [86] Molecular determinants of retinoic acid sensitivity in pancreatic cancer.Clin Cancer Res. 2012 Jan 1;18(1):280-9. doi: 10.1158/1078-0432.CCR-11-2165. Epub 2011 Oct 18.
• [87] Emergence of heterogeneous nuclear ribonucleoprotein A2/B1 vs loss of E-cadherin: their reciprocal immunoexpression profiles in human pancreatic cancer.Ann Diagn Pathol. 2013 Feb;17(1):14-7. doi: 10.1016/j.anndiagpath.2012.04.004. Epub 2012 May 22.
• [88] Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.Mol Cancer Ther. 2014 Feb;13(2):307-315. doi: 10.1158/1535-7163.MCT-13-0324. Epub 2013 Nov 26.
• [89] Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma.Br J Cancer. 2008 Nov 4;99(9):1484-92. doi: 10.1038/sj.bjc.6604717. Epub 2008 Oct 14.
• [90] Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.
• [91] Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer.Cancer Cell. 2013 Mar 18;23(3):406-20. doi: 10.1016/j.ccr.2013.01.023. Epub 2013 Feb 28.
• [92] Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.Oncotarget. 2015 Nov 10;6(35):37028-42. doi: 10.18632/oncotarget.5939.
• [93] SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9.Tumour Biol. 2014 Dec;35(12):12729-35. doi: 10.1007/s13277-014-2598-1. Epub 2014 Sep 13.
• [94] Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.Mol Cell Proteomics. 2014 Dec;13(12):3484-96. doi: 10.1074/mcp.M113.036517. Epub 2014 Sep 15.
• [95] AQP1 and AQP3 Expression are Associated With Severe Symptoms and Poor-prognosis of the Pancreatic Ductal Adenocarcinoma.Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):40-47. doi: 10.1097/PAI.0000000000000523.
• [96] CD13(hi) Neutrophil-like myeloid-derived suppressor cells exert immune suppression through Arginase 1 expression in pancreatic ductal adenocarcinoma.Oncoimmunology. 2017 Jan 9;6(2):e1258504. doi: 10.1080/2162402X.2016.1258504. eCollection 2017.
• [97] Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.Mol Carcinog. 2019 Oct;58(10):1908-1918. doi: 10.1002/mc.23084. Epub 2019 Jul 16.
• [98] Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.
• [99] MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.Lab Invest. 2011 Oct;91(10):1472-9. doi: 10.1038/labinvest.2011.99. Epub 2011 Jun 27.
• [100] CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.Mol Pharmacol. 2019 Oct;96(4):419-429. doi: 10.1124/mol.119.116855.
• [101] Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.Sci Rep. 2019 Dec 4;9(1):18347. doi: 10.1038/s41598-019-54545-9.
• [102] dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.Medicine (Baltimore). 2016 Mar;95(10):e2936. doi: 10.1097/MD.0000000000002936.
• [103] Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis.J Cancer. 2019 Jan 29;10(4):911-917. doi: 10.7150/jca.27405. eCollection 2019.
• [104] Overexpressions of DLL4 and CD105 are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.Pathol Oncol Res. 2015 Sep;21(4):1141-7. doi: 10.1007/s12253-015-9937-4. Epub 2015 May 19.
• [105] Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Chem Biol Interact. 2020 Jan 25;316:108913. doi: 10.1016/j.cbi.2019.108913. Epub 2019 Dec 12.
• [106] Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.Cancer Biol Ther. 2009 Sep;8(17):1671-9. doi: 10.4161/cbt.8.17.9322. Epub 2009 Sep 20.
• [107] Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.Biomed Res Int. 2017;2017:2847303. doi: 10.1155/2017/2847303. Epub 2017 Oct 25.
• [108] Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.Cell Commun Signal. 2019 Aug 30;17(1):111. doi: 10.1186/s12964-019-0425-4.
• [109] Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.
• [110] BAG3 deletion suppresses stem cell-like features of pancreatic ductal adenocarcinoma via translational suppression of ISG15.Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):819-827. doi: 10.1016/j.bbamcr.2019.02.008. Epub 2019 Feb 14.
• [111] Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2019 Nov;215(11):152623. doi: 10.1016/j.prp.2019.152623. Epub 2019 Sep 5.
• [112] Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice.BMC Cancer. 2018 Aug 7;18(1):797. doi: 10.1186/s12885-018-4713-y.
• [113] Differentially Expressed microRNAs in MIA PaCa-2 and PANC-1 Pancreas Ductal Adenocarcinoma Cell Lines are Involved in Cancer Stem Cell Regulation.Int J Mol Sci. 2019 Sep 10;20(18):4473. doi: 10.3390/ijms20184473.
• [114] Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.
• [115] Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.Pancreas. 2003 Apr;26(3):e48-54. doi: 10.1097/00006676-200304000-00022.
• [116] Immunohistochemical expression of NEDD9, E-cadherin and -catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).Bosn J Basic Med Sci. 2018 Aug 1;18(3):246-251. doi: 10.17305/bjbms.2018.2378.
• [117] Stem cell marker nestin is critical for TGF-1-mediated tumor progression in pancreatic cancer.Mol Cancer Res. 2013 Jul;11(7):768-79. doi: 10.1158/1541-7786.MCR-12-0511. Epub 2013 Apr 3.
• [118] Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer.Clin Cancer Res. 2003 Nov 1;9(14):5127-36.
• [119] Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis.Int J Cancer. 2005 Oct 10;116(6):925-33. doi: 10.1002/ijc.21118.
• [120] Cationic trypsinogen mutations and pancreatitis.Clin Lab Med. 2005 Mar;25(1):39-59. doi: 10.1016/j.cll.2004.12.004.
• [121] Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019 Sep;51(9):1308-1314. doi: 10.1038/s41588-019-0475-y. Epub 2019 Aug 12.
• [122] Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis.Onco Targets Ther. 2019 Feb 1;12:1007-1020. doi: 10.2147/OTT.S176101. eCollection 2019.
• [123] Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.PLoS One. 2013;8(1):e53436. doi: 10.1371/journal.pone.0053436. Epub 2013 Jan 15.
• [124] SERPINB5 Promoter Hypomethylation Differentiates Pancreatic Ductal Adenocarcinoma From Pancreatitis.Pancreas. 2016 May-Jun;45(5):743-7. doi: 10.1097/MPA.0000000000000526.
• [125] Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?.Cancers (Basel). 2019 Oct 23;11(11):1621. doi: 10.3390/cancers11111621.
• [126] Aberrant expressions of AP-2 splice variants in pancreatic cancer.Pancreas. 2011 Jul;40(5):695-700. doi: 10.1097/MPA.0b013e31821f2715.
• [127] N-glycosylation of the transient receptor potential melastatin 8 channel is altered in pancreatic cancer cells.Tumour Biol. 2017 Aug;39(8):1010428317720940. doi: 10.1177/1010428317720940.
• [128] Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.PLoS One. 2017 Apr 5;12(4):e0174863. doi: 10.1371/journal.pone.0174863. eCollection 2017.
• [129] Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis.PLoS One. 2018 Feb 23;13(2):e0193125. doi: 10.1371/journal.pone.0193125. eCollection 2018.
• [130] DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2019 Aug 2;11(8):1101. doi: 10.3390/cancers11081101.
• [131] YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.JCI Insight. 2019 Nov 1;4(21):e130811. doi: 10.1172/jci.insight.130811.
• [132] ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.Mol Oncol. 2019 Feb;13(2):456-479. doi: 10.1002/1878-0261.12426. Epub 2019 Jan 9.
• [133] Anti-tumor activity of antibody drug conjugate targeting aspartate--hydroxylase in pancreatic ductal adenocarcinoma.Cancer Lett. 2019 May 1;449:87-98. doi: 10.1016/j.canlet.2019.02.006. Epub 2019 Feb 12.
• [134] High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.Gene. 2019 Jun 15;701:15-22. doi: 10.1016/j.gene.2019.02.081. Epub 2019 Mar 18.
• [135] High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients.Eur J Surg Oncol. 2019 Feb;45(2):207-212. doi: 10.1016/j.ejso.2018.09.020. Epub 2018 Oct 21.
• [136] Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer.Pancreatology. 2019 Oct;19(7):951-956. doi: 10.1016/j.pan.2019.09.009. Epub 2019 Sep 20.
• [137] DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma.J Immunol Res. 2019 Sep 8;2019:8656282. doi: 10.1155/2019/8656282. eCollection 2019.
• [138] Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2019 May;145(5):1165-1178. doi: 10.1007/s00432-019-02863-w. Epub 2019 Feb 18.
• [139] MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.Technol Cancer Res Treat. 2019 Jan 1;18:1533033818824314. doi: 10.1177/1533033818824314.
• [140] Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.Gastroenterology. 2020 Apr;158(5):1433-1449.e27. doi: 10.1053/j.gastro.2019.11.279. Epub 2019 Nov 29.
• [141] B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Feb;110(2):530-539. doi: 10.1111/cas.13914. Epub 2019 Jan 16.
• [142] A SLC24A2 Gene Variant Uncovered in Pancreatic Ductal Adenocarcinoma by Whole Exome Sequencing.Tohoku J Exp Med. 2017 Apr;241(4):287-295. doi: 10.1620/tjem.241.287.
• [143] TGF--induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.Carcinogenesis. 2016 Nov 1;37(11):1041-1051. doi: 10.1093/carcin/bgw093.
• [144] Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis.Aging (Albany NY). 2019 May 8;11(9):2681-2698. doi: 10.18632/aging.101940.
• [145] Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.J Natl Cancer Inst. 2015 May 29;107(8):djv132. doi: 10.1093/jnci/djv132. Print 2015 Aug.
• [146] Differential expression of cytochrome P450 omega-hydroxylase isoforms and their association with clinicopathological features in pancreatic ductal adenocarcinoma.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S636-43. doi: 10.1245/s10434-013-3128-x. Epub 2013 Jul 12.
• [147] Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition.PLoS One. 2013 Dec 18;8(12):e83021. doi: 10.1371/journal.pone.0083021. eCollection 2013.
• [148] Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 29;8(32):53180-53193. doi: 10.18632/oncotarget.18261. eCollection 2017 Aug 8.
• [149] CCR7 regulates ANO6 to promote migration of pancreatic ductal adenocarcinoma cells via the ERK signaling pathway.Oncol Lett. 2018 Aug;16(2):2599-2605. doi: 10.3892/ol.2018.8962. Epub 2018 Jun 13.
• [150] Differential expression of aquaporin-3 and aquaporin-5 in pancreatic ductal adenocarcinoma.J Surg Oncol. 2017 Jun;115(8):980-996. doi: 10.1002/jso.24605. Epub 2017 May 4.
• [151] Decreased expression of ARHGAP15 promotes the development of colorectal cancer through PTEN/AKT/FOXO1 axis.Cell Death Dis. 2018 Jun 4;9(6):673. doi: 10.1038/s41419-018-0707-6.
• [152] ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.Mol Cancer. 2016 May 4;15(1):32. doi: 10.1186/s12943-016-0516-4.
• [153] Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.Technol Cancer Res Treat. 2018 Jan 1;17:1533034618754475. doi: 10.1177/1533034618754475.
• [154] Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells.Cancer Biol Ther. 2007 Mar;6(3):367-76. doi: 10.4161/cbt.6.3.3704. Epub 2007 Mar 13.
• [155] Clinicopathological significance of Necl-4 expression in pancreatic ductal adenocarcinoma.J Clin Pathol. 2017 Jul;70(7):619-624. doi: 10.1136/jclinpath-2016-204028. Epub 2016 Dec 15.
• [156] Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells.Front Oncol. 2017 Sep 29;7:239. doi: 10.3389/fonc.2017.00239. eCollection 2017.
• [157] Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma.Oncogene. 2015 Aug 6;34(32):4238-47. doi: 10.1038/onc.2014.357. Epub 2014 Nov 10.
• [158] The C/EBP-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1.Cancer Lett. 2018 May 1;421:63-72. doi: 10.1016/j.canlet.2018.02.020. Epub 2018 Feb 16.
• [159] Association of chloride intracellular channel 4 and Indian hedgehog proteins with survival of patients with pancreatic ductal adenocarcinoma.Int J Exp Pathol. 2016 Dec;97(6):422-429. doi: 10.1111/iep.12213. Epub 2017 Feb 16.
• [160] Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 9;8(34):56428-56442. doi: 10.18632/oncotarget.17701. eCollection 2017 Aug 22.
• [161] Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.Cancer Biol Ther. 2019;20(7):949-955. doi: 10.1080/15384047.2019.1595274. Epub 2019 Apr 19.
• [162] COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.Mol Carcinog. 2017 Feb;56(2):607-624. doi: 10.1002/mc.22520. Epub 2016 Jul 8.
• [163] CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis.Cancer Biol Ther. 2019;20(9):1290-1299. doi: 10.1080/15384047.2019.1632143. Epub 2019 Jul 16.
• [164] Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.Diagn Pathol. 2017 May 30;12(1):42. doi: 10.1186/s13000-017-0633-4.
• [165] Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for earlystage pancreatic ductal adenocarcinoma.Oncol Rep. 2019 Jul;42(1):79-90. doi: 10.3892/or.2019.7135. Epub 2019 Apr 24.
• [166] Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma.Cancer Sci. 2017 Nov;108(11):2122-2129. doi: 10.1111/cas.13396. Epub 2017 Oct 8.
• [167] Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.Oncotarget. 2017 Jun 13;8(24):38276-38293. doi: 10.18632/oncotarget.11299.
• [168] Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.World J Gastroenterol. 2017 Aug 21;23(31):5764-5772. doi: 10.3748/wjg.v23.i31.5764.
• [169] High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma.Pathol Oncol Res. 2015 Apr;21(2):267-72. doi: 10.1007/s12253-014-9817-3. Epub 2014 Jul 31.
• [170] Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.J Mol Cell Biol. 2017 Dec 1;9(6):504-515. doi: 10.1093/jmcb/mjx043.
• [171] Dual oxidase 2 and pancreatic adenocarcinoma: IFN--mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1 and VEGF-A.Oncotarget. 2016 Oct 18;7(42):68412-68433. doi: 10.18632/oncotarget.12032.
• [172] EFNB2 acts as the target of miR-557 to facilitate cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma by bioinformatics analysis and verification.Am J Transl Res. 2018 Nov 15;10(11):3514-3528. eCollection 2018.
• [173] EI24 Suppresses Tumorigenesis in Pancreatic Cancer via Regulating c-Myc.Gastroenterol Res Pract. 2018 Oct 2;2018:2626545. doi: 10.1155/2018/2626545. eCollection 2018.
• [174] Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma.Onco Targets Ther. 2019 Apr 15;12:2853-2859. doi: 10.2147/OTT.S202101. eCollection 2019.
• [175] Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer.J Korean Med Sci. 2016 Oct;31(10):1586-94. doi: 10.3346/jkms.2016.31.10.1586.
• [176] Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF- pathway.Mol Carcinog. 2016 May;55(5):633-45. doi: 10.1002/mc.22309. Epub 2015 Mar 14.
• [177] EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through -catenin/ID2 pathway.Cancer Lett. 2016 Oct 1;380(2):403-412. doi: 10.1016/j.canlet.2016.06.021. Epub 2016 Jul 1.
• [178] FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2018 Sep 10;37(1):224. doi: 10.1186/s13046-018-0888-y.
• [179] FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jan 18;9(2):34. doi: 10.1038/s41419-017-0052-1.
• [180] Membranous CD24 drives the epithelial phenotype of pancreatic cancer.Oncotarget. 2016 Aug 2;7(31):49156-49168. doi: 10.18632/oncotarget.9402.
• [181] Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.Pancreatology. 2018 Jun;18(4):407-412. doi: 10.1016/j.pan.2018.04.003. Epub 2018 Apr 3.
• [182] GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.Mol Med Rep. 2018 Mar;17(3):4187-4194. doi: 10.3892/mmr.2018.8430. Epub 2018 Jan 15.
• [183] High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5.Biochem Biophys Res Commun. 2018 Feb 26;497(1):73-79. doi: 10.1016/j.bbrc.2018.02.023. Epub 2018 Feb 3.
• [184] GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.Cell Death Dis. 2016 Jul 14;7(7):e2294. doi: 10.1038/cddis.2016.169.
• [185] HMGN5 promotes proliferation and invasion via the activation of Wnt/-catenin signaling pathway in pancreatic ductal adenocarcinoma.Oncol Lett. 2018 Sep;16(3):4013-4019. doi: 10.3892/ol.2018.9090. Epub 2018 Jul 5.
• [186] Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2017 Jun;143(6):1061-1068. doi: 10.1007/s00432-017-2351-4. Epub 2017 Feb 17.
• [187] IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC.Cell Rep. 2016 May 31;15(9):1876-83. doi: 10.1016/j.celrep.2016.04.083. Epub 2016 May 19.
• [188] NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-B activation.Cancer Lett. 2017 Dec 28;411:44-56. doi: 10.1016/j.canlet.2017.09.018. Epub 2017 Sep 23.
• [189] The Insulin-Like Growth Factor 2 mRNA Binding Protein IMP2/IGF2BP2 is Overexpressed and Correlates with Poor Survival in Pancreatic Cancer.Int J Mol Sci. 2019 Jun 29;20(13):3204. doi: 10.3390/ijms20133204.
• [190] KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras(G12D) p53(flox/flox) model.Oncogene. 2017 Sep 28;36(39):5532-5543. doi: 10.1038/onc.2017.155. Epub 2017 Jun 5.
• [191] Latent Transforming Growth Factor Binding Protein 2 (LTBP2) as a Novel Biomarker for the Diagnosis and Prognosis of Pancreatic Carcinoma.Med Sci Monit. 2017 Jul 3;23:3232-3239. doi: 10.12659/msm.905284.
• [192] Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.PLoS One. 2016 Mar 29;11(3):e0152300. doi: 10.1371/journal.pone.0152300. eCollection 2016.
• [193] Prognostic value of minichromosome maintenance mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy.Cancer Manag Res. 2018 Sep 5;10:3255-3271. doi: 10.2147/CMAR.S171293. eCollection 2018.
• [194] PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.Neoplasia. 2018 Jan;20(1):12-24. doi: 10.1016/j.neo.2017.10.004. Epub 2017 Nov 23.
• [195] Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.HPB (Oxford). 2018 Jun;20(6):563-572. doi: 10.1016/j.hpb.2017.12.003. Epub 2018 Jan 17.
• [196] Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.Scand J Gastroenterol. 2017 May;52(5):595-600. doi: 10.1080/00365521.2017.1290134. Epub 2017 Feb 15.
• [197] High expression of diffuse panbronchiolitis critical region 1 gene promotes cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 8;495(2):1908-1914. doi: 10.1016/j.bbrc.2017.12.031. Epub 2017 Dec 11.
• [198] Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.Pathol Res Pract. 2017 Aug;213(8):964-968. doi: 10.1016/j.prp.2017.04.024. Epub 2017 May 4.
• [199] Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness.Oncogene. 2018 Aug;37(32):4398-4412. doi: 10.1038/s41388-018-0287-z. Epub 2018 May 3.
• [200] Nectin-1 expression in cancer-associated fibroblasts is a predictor of poor prognosis for pancreatic ductal adenocarcinoma.Surg Today. 2018 May;48(5):510-516. doi: 10.1007/s00595-017-1618-3. Epub 2017 Dec 18.
• [201] Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells.Cell Death Dis. 2018 Feb 12;9(2):210. doi: 10.1038/s41419-017-0191-4.
• [202] Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.DNA Repair (Amst). 2019 Nov;83:102644. doi: 10.1016/j.dnarep.2019.102644. Epub 2019 Jul 5.
• [203] Amphipathic helical peptides hamper protein-protein interactions of the intrinsically disordered chromatin nuclear protein 1 (NUPR1).Biochim Biophys Acta Gen Subj. 2018 Jun;1862(6):1283-1295. doi: 10.1016/j.bbagen.2018.03.009. Epub 2018 Mar 10.
• [204] OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.Pancreatology. 2019 Jul;19(5):751-759. doi: 10.1016/j.pan.2019.01.009. Epub 2019 Jan 31.
• [205] Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis.Transl Res. 2019 Oct;212:67-79. doi: 10.1016/j.trsl.2019.06.003. Epub 2019 Jun 29.
• [206] PAFAH1B2 is a HIF1a target gene and promotes metastasis in pancreatic cancer.Biochem Biophys Res Commun. 2018 Jun 27;501(3):654-660. doi: 10.1016/j.bbrc.2018.05.039. Epub 2018 May 16.
• [207] 2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.Cancer Lett. 2016 Apr 1;373(1):67-76. doi: 10.1016/j.canlet.2016.01.026. Epub 2016 Jan 21.
• [208] High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.BMC Cancer. 2019 May 14;19(1):452. doi: 10.1186/s12885-019-5616-2.
• [209] Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.Cancer Sci. 2019 Jul;110(7):2296-2308. doi: 10.1111/cas.14041. Epub 2019 Jun 18.
• [210] Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.Cancer Res. 2016 Nov 15;76(22):6507-6519. doi: 10.1158/0008-5472.CAN-15-2864. Epub 2016 Sep 9.
• [211] PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.Oncotarget. 2016 Feb 16;7(7):7801-15. doi: 10.18632/oncotarget.6848.
• [212] Expression of polymeric immunoglobulin receptor and stromal activity in pancreatic ductal adenocarcinoma.Pancreatology. 2017 Mar-Apr;17(2):295-302. doi: 10.1016/j.pan.2017.01.013. Epub 2017 Feb 1.
• [213] Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1296-305. doi: 10.1073/pnas.1513801113. Epub 2016 Feb 16.
• [214] Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells.J Cell Biochem. 2018 Aug;119(8):6644-6656. doi: 10.1002/jcb.26847. Epub 2018 Apr 17.
• [215] GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.Gut. 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20.
• [216] Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells.Pancreas. 2017 Oct;46(9):1173-1179. doi: 10.1097/MPA.0000000000000910.
• [217] Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.Cell Death Dis. 2017 Sep 7;8(9):e3033. doi: 10.1038/cddis.2017.424.
• [218] Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer.Sci Rep. 2016 Mar 14;6:22996. doi: 10.1038/srep22996.
• [219] Ro60/SSA levels are increased and promote the progression of pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Jan 22;495(4):2519-2524. doi: 10.1016/j.bbrc.2017.12.124. Epub 2017 Dec 22.
• [220] Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma.Oncotarget. 2017 May 18;8(38):62953-62961. doi: 10.18632/oncotarget.17972. eCollection 2017 Sep 8.
• [221] Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.Nanoscale. 2017 Jul 27;9(29):10327-10334. doi: 10.1039/c7nr03042h.
• [222] Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway.Cancer Lett. 2017 Jul 1;397:12-22. doi: 10.1016/j.canlet.2017.03.014. Epub 2017 Mar 14.
• [223] SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-B axis.Int J Oncol. 2017 Oct;51(4):1104-1114. doi: 10.3892/ijo.2017.4111. Epub 2017 Aug 31.
• [224] Promoter hypomethylation of SKI in autoimmune pancreatitis.Pathol Res Pract. 2018 Apr;214(4):492-497. doi: 10.1016/j.prp.2018.03.005. Epub 2018 Mar 6.
• [225] MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma.Biochem Biophys Res Commun. 2018 Mar 18;497(4):963-970. doi: 10.1016/j.bbrc.2018.02.005. Epub 2018 Mar 1.
• [226] SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.Oncogene. 2018 Feb 15;37(7):912-923. doi: 10.1038/onc.2017.393. Epub 2017 Oct 23.
• [227] Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.Neoplasia. 2007 Jan;9(1):8-17. doi: 10.1593/neo.06646.
• [228] Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.J Cancer. 2018 Feb 1;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.
• [229] APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.Mol Oncol. 2017 Dec;11(12):1711-1732. doi: 10.1002/1878-0261.12138. Epub 2017 Oct 19.
• [230] MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2018 Apr 3;37(1):76. doi: 10.1186/s13046-018-0739-x.
• [231] Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF- signaling pathway.J Exp Clin Cancer Res. 2019 Jul 15;38(1):310. doi: 10.1186/s13046-019-1313-x.
• [232] Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.Ann Surg Oncol. 2019 Mar;26(3):807-814. doi: 10.1245/s10434-018-07109-6. Epub 2018 Dec 19.
• [233] ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles.Mol Ther Methods Clin Dev. 2019 Sep 12;15:204-210. doi: 10.1016/j.omtm.2019.08.016. eCollection 2019 Dec 13.
• [234] Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma.J Exp Clin Cancer Res. 2019 Nov 12;38(1):466. doi: 10.1186/s13046-019-1436-0.
• [235] Five Novel Genes Related to the Pathogenesis and Progression of Pancreatic Neuroendocrine Tumors by Bioinformatics Analysis With RT-qPCR Verification.Front Neurosci. 2019 Sep 24;13:937. doi: 10.3389/fnins.2019.00937. eCollection 2019.
• [236] eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.Nat Commun. 2019 Nov 13;10(1):5151. doi: 10.1038/s41467-019-13086-5.
• [237] Forkhead box B2 inhibits the malignant characteristics of the pancreatic cancer cell line Panc-1 in vitro.Genes Cells. 2019 Oct;24(10):674-681. doi: 10.1111/gtc.12717. Epub 2019 Oct 7.
• [238] Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects.Sci Rep. 2019 Oct 29;9(1):15471. doi: 10.1038/s41598-019-51881-8.
• [239] Modeling Human Cancer-induced Cachexia.Cell Rep. 2019 Aug 6;28(6):1612-1622.e4. doi: 10.1016/j.celrep.2019.07.016.
• [240] RASAL2 Plays Inconsistent Roles in Different Cancers.Front Oncol. 2019 Nov 13;9:1235. doi: 10.3389/fonc.2019.01235. eCollection 2019.
• [241] IFN- down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.BMC Cancer. 2019 Nov 6;19(1):1053. doi: 10.1186/s12885-019-6145-8.
• [242] lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP.Clin Cancer Res. 2020 Apr 1;26(7):1736-1748. doi: 10.1158/1078-0432.CCR-19-0674. Epub 2019 Dec 12.
• [243] ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.Mol Med Rep. 2013 Mar;7(3):991-7. doi: 10.3892/mmr.2013.1272. Epub 2013 Jan 11.
• [244] SERPINB5 and AKAP12 - expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma.BMC Cancer. 2010 Oct 12;10:549. doi: 10.1186/1471-2407-10-549.
• [245] Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.Biol Chem. 2012 Aug;393(8):785-99. doi: 10.1515/hsz-2012-0165.
• [246] Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma.Dig Dis Sci. 2011 Apr;56(4):1090-8. doi: 10.1007/s10620-010-1416-x. Epub 2010 Oct 7.
• [247] Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.Clin Cancer Res. 2011 Oct 1;17(19):6140-50. doi: 10.1158/1078-0432.CCR-10-2288. Epub 2011 Aug 8.
• [248] Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.Dev Cell. 2012 Jan 17;22(1):131-45. doi: 10.1016/j.devcel.2011.11.008. Epub 2011 Dec 22.
• [249] CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells.Cancer Res. 2014 May 15;74(10):2785-95. doi: 10.1158/0008-5472.CAN-13-3176. Epub 2014 Mar 19.
• [250] Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid.Cancer Res. 2014 Nov 1;74(21):6224-35. doi: 10.1158/0008-5472.CAN-14-0819. Epub 2014 Sep 9.
• [251] DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Oct;34(5):2857-61. doi: 10.1007/s13277-013-0846-4. Epub 2013 May 17.
• [252] Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex.PLoS One. 2013 Dec 5;8(12):e79654. doi: 10.1371/journal.pone.0079654. eCollection 2013.
• [253] Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.Oncogene. 2014 Sep 4;33(36):4485-95. doi: 10.1038/onc.2013.392. Epub 2013 Sep 30.
• [254] FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.
• [255] The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2015 Dec;36(12):9961-8. doi: 10.1007/s13277-015-3752-0. Epub 2015 Jul 16.
• [256] Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma.BMC Cancer. 2014 Aug 7;14:571. doi: 10.1186/1471-2407-14-571.
• [257] Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.Br J Cancer. 2011 Jul 12;105(2):288-95. doi: 10.1038/bjc.2011.217. Epub 2011 Jun 28.
• [258] NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.Mol Cell Biochem. 2015 Dec;410(1-2):25-35. doi: 10.1007/s11010-015-2535-7. Epub 2015 Aug 15.
• [259] Integrated microRNA-mRNA analysis of pancreatic ductal adenocarcinoma.Genet Mol Res. 2015 Aug 28;14(3):10288-97. doi: 10.4238/2015.August.28.14.
• [260] Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma.Mol Biol Rep. 2014 Dec;41(12):8163-7. doi: 10.1007/s11033-014-3716-2. Epub 2014 Oct 17.
• [261] Transforming Growth Factor TGF Increases Levels of Microtubule-Associated Protein MAP1S and Autophagy Flux in Pancreatic Ductal Adenocarcinomas.PLoS One. 2015 Nov 16;10(11):e0143150. doi: 10.1371/journal.pone.0143150. eCollection 2015.
• [262] Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.J Clin Invest. 2014 Mar;124(3):1069-82. doi: 10.1172/JCI67280.
• [263] Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31.
• [264] Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6181-91. eCollection 2015.
• [265] High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).Tumour Biol. 2015 Dec;36(12):9189-99. doi: 10.1007/s13277-015-3625-6. Epub 2015 Jun 19.
• [266] Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma.Tumour Biol. 2013 Oct;34(5):2983-7. doi: 10.1007/s13277-013-0862-4. Epub 2013 May 22.
• [267] Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.PLoS One. 2015 Jun 8;10(6):e0129012. doi: 10.1371/journal.pone.0129012. eCollection 2015.
• [268] Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases.Mol Cancer Res. 2011 Dec;9(12):1621-31. doi: 10.1158/1541-7786.MCR-11-0018. Epub 2011 Oct 11.
• [269] Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Mol Cancer Ther. 2014 Jan;13(1):122-33. doi: 10.1158/1535-7163.MCT-12-1232. Epub 2013 Nov 12.
• [270] Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.World J Gastroenterol. 2015 Jun 7;21(21):6621-30. doi: 10.3748/wjg.v21.i21.6621.
• [271] Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells.Cancer Res. 2014 Aug 15;74(16):4353-63. doi: 10.1158/0008-5472.CAN-14-0181. Epub 2014 Jun 5.
• [272] SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4791-8. eCollection 2015.
• [273] SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell.Cancer Res. 2008 Oct 1;68(19):7723-9. doi: 10.1158/0008-5472.CAN-07-6661.
• [274] Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.Int J Mol Sci. 2011;12(8):4953-63. doi: 10.3390/ijms12084953. Epub 2011 Aug 3.
• [275] TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.PLoS One. 2015 Dec 28;10(12):e0144969. doi: 10.1371/journal.pone.0144969. eCollection 2015.
• [276] TRIM29 as a novel biomarker in pancreatic adenocarcinoma.Dis Markers. 2014;2014:317817. doi: 10.1155/2014/317817. Epub 2014 Apr 22.
• [277] Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.Cancer Res. 2010 May 15;70(10):4024-33. doi: 10.1158/0008-5472.CAN-09-4444. Epub 2010 May 4.
• [278] Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.Cancer Biol Ther. 2005 Mar;4(3):302-7. doi: 10.4161/cbt.4.3.1501. Epub 2005 Mar 23.
• [279] Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 May 1;9(5):453. doi: 10.1038/s41419-018-0486-0.
• [280] Utilization of CDX2 expression in diagnosing pancreatic ductal adenocarcinoma and predicting prognosis.PLoS One. 2014 Jan 29;9(1):e86853. doi: 10.1371/journal.pone.0086853. eCollection 2014.
• [281] KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer.Oncotarget. 2017 Mar 7;8(10):17156-17163. doi: 10.18632/oncotarget.15052.
• [282] CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.Oncotarget. 2016 Mar 22;7(12):14831-40. doi: 10.18632/oncotarget.7447.
• [283] Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma.PLoS One. 2016 May 9;11(5):e0155025. doi: 10.1371/journal.pone.0155025. eCollection 2016.
• [284] CRABP-II enhances pancreatic cancer cell migration and invasion by stabilizing interleukin 8 expression.Oncotarget. 2016 Dec 26;8(32):52432-52444. doi: 10.18632/oncotarget.14194. eCollection 2017 Aug 8.
• [285] MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.Cell Death Dis. 2018 Jul 24;9(8):807. doi: 10.1038/s41419-018-0839-8.
• [286] Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis.Cancer Cell Int. 2018 Oct 22;18:166. doi: 10.1186/s12935-018-0651-7. eCollection 2018.
• [287] CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma.Transl Oncol. 2019 Nov;12(11):1395-1403. doi: 10.1016/j.tranon.2019.07.009. Epub 2019 Aug 7.
• [288] HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.Cancer Lett. 2019 Feb 1;442:333-340. doi: 10.1016/j.canlet.2018.11.007. Epub 2018 Nov 14.
• [289] Acetylated HOXB9 at lysine 27 is of differential diagnostic value in patients with pancreatic ductal adenocarcinoma.Front Med. 2020 Feb;14(1):91-100. doi: 10.1007/s11684-019-0696-6. Epub 2019 Aug 2.
• [290] Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA.Acta Biochim Biophys Sin (Shanghai). 2019 Jul 10;51(7):743-752. doi: 10.1093/abbs/gmz048.
• [291] Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.Amino Acids. 2017 Aug;49(8):1325-1335. doi: 10.1007/s00726-017-2430-5. Epub 2017 May 23.
• [292] IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis.Pancreas. 2019 Jan;48(1):94-98. doi: 10.1097/MPA.0000000000001198.
• [293] Krppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5.Biochem Biophys Res Commun. 2018 May 23;499(4):815-821. doi: 10.1016/j.bbrc.2018.03.229. Epub 2018 Apr 4.
• [294] Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.Sci Rep. 2017 Nov 30;7(1):16623. doi: 10.1038/s41598-017-16811-6.
• [295] LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.J Exp Clin Cancer Res. 2019 Feb 13;38(1):75. doi: 10.1186/s13046-019-1088-0.
• [296] Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.Cell Death Differ. 2019 Jan;26(2):382-393. doi: 10.1038/s41418-018-0207-3. Epub 2018 Oct 3.
• [297] MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.Cell Death Dis. 2019 Feb 27;10(3):206. doi: 10.1038/s41419-019-1424-5.
• [298] Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.Oncogene. 2018 Nov;37(46):6041-6053. doi: 10.1038/s41388-018-0403-0. Epub 2018 Jul 11.
• [299] Nardilysin inhibits pancreatitis and suppresses pancreatic ductal adenocarcinoma initiation in mice.Gut. 2019 May;68(5):882-892. doi: 10.1136/gutjnl-2017-315425. Epub 2018 May 24.
• [300] High-resolution genomic profiles of human lung cancer.Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30. doi: 10.1073/pnas.0504126102. Epub 2005 Jun 27.
• [301] Evidence of (68)Ga-DOTA-NT-20.3 Uptake in Pancreatic Adenocarcinoma AsPC-1 Cell Line - in vitro Study.Curr Pharm Biotechnol. 2018;19(9):754-759. doi: 10.2174/1389201019666180829152314.
• [302] Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.Sci Rep. 2018 May 25;8(1):8105. doi: 10.1038/s41598-018-26526-x.
• [303] Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.Pancreas. 2017 Jan;46(1):28-34. doi: 10.1097/MPA.0000000000000725.
• [304] Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.Nanoscale. 2017 Oct 19;9(40):15622-15634. doi: 10.1039/c7nr03172f.
• [305] High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma.Mol Cancer. 2015 Apr 28;14:95. doi: 10.1186/s12943-015-0356-7.
• [306] Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.Mol Oncol. 2018 Jun;12(7):1104-1124. doi: 10.1002/1878-0261.12314. Epub 2018 May 21.
• [307] Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.Br J Cancer. 1998;77(1):147-52. doi: 10.1038/bjc.1998.23.
• [308] Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.Mol Carcinog. 2014 Sep;53(9):711-21. doi: 10.1002/mc.22023. Epub 2013 May 9.
• [309] Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.Mol Cancer. 2019 May 20;18(1):96. doi: 10.1186/s12943-019-1023-1.
• [310] Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?.Autophagy. 2019 Feb;15(2):368-371. doi: 10.1080/15548627.2018.1509609. Epub 2018 Sep 13.
• [311] Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.Oncogene. 2020 Jan;39(2):308-321. doi: 10.1038/s41388-019-0985-1. Epub 2019 Sep 2.
• [312] Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis.Oncotarget. 2019 Jan 11;10(4):558. doi: 10.18632/oncotarget.26597. eCollection 2019 Jan 11.
• [313] Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.J Exp Med. 2019 Mar 4;216(3):656-673. doi: 10.1084/jem.20180749. Epub 2019 Feb 7.
• [314] Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8.J Hum Genet. 2019 Jun;64(6):521-534. doi: 10.1038/s10038-019-0584-6. Epub 2019 Mar 11.
• [315] FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.J Cell Biochem. 2020 Mar;121(3):2458-2466. doi: 10.1002/jcb.29468. Epub 2019 Nov 6.
• [316] Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma.Oncogene. 2019 Jun;38(26):5308-5320. doi: 10.1038/s41388-019-0794-6. Epub 2019 Mar 27.
• [317] Insulinoma-associated protein 1 expression in pancreatic neuroendocrine tumours in endoscopic ultrasound-guided fine-needle aspiration cytology: An analysis of 14 patients.Cytopathology. 2019 Mar;30(2):194-200. doi: 10.1111/cyt.12640. Epub 2018 Dec 17.
• [318] KAT2A succinyltransferase activity-mediated 14-3-3 upregulation promotes -catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells.Cancer Lett. 2020 Jan 28;469:1-10. doi: 10.1016/j.canlet.2019.09.015. Epub 2019 Oct 11.
• [319] HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.Pathol Res Pract. 2019 Feb;215(2):343-346. doi: 10.1016/j.prp.2018.12.016. Epub 2018 Dec 12.
• [320] LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation.Clin Cancer Res. 2019 Jul 1;25(13):4091-4103. doi: 10.1158/1078-0432.CCR-18-3533. Epub 2019 Jan 24.
• [321] TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.Autophagy. 2020 Mar;16(3):486-500. doi: 10.1080/15548627.2019.1628540. Epub 2019 Jun 17.
• [322] Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.Hum Pathol. 2019 Apr;86:143-154. doi: 10.1016/j.humpath.2018.11.026. Epub 2018 Dec 9.
• [323] MDH1 and MPP7 Regulate Autophagy in Pancreatic Ductal Adenocarcinoma.Cancer Res. 2019 Apr 15;79(8):1884-1898. doi: 10.1158/0008-5472.CAN-18-2553. Epub 2019 Feb 14.
• [324] Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30.
• [325] Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis.Pancreatology. 2019 Apr;19(3):443-448. doi: 10.1016/j.pan.2019.03.001. Epub 2019 Mar 11.
• [326] POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma.Oncotarget. 2019 Feb 22;10(16):1572-1588. doi: 10.18632/oncotarget.26705. eCollection 2019 Feb 22.
• [327] Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation.Cancers (Basel). 2019 Mar 7;11(3):327. doi: 10.3390/cancers11030327.
• [328] Downregulation of thymopoietin by miR-139-5p suppresses cell proliferation and induces cell cycle arrest/apoptosis in pancreatic ductal adenocarcinoma.Oncol Lett. 2019 Oct;18(4):3443-3452. doi: 10.3892/ol.2019.10679. Epub 2019 Jul 29.